2seventy bio to Participate in Upcoming Investor Conferences

Rhea-AI Summary

2seventy bio, Inc. (Nasdaq: TSVT) announced participation in two upcoming investor conferences. The first event is the Guggenheim Oncology Conference on February 9 at 9:00 am ET, held at the St. Regis New York. The second is the SVB Securities Global Biopharma Conference on February 15 at 10:00 am ET, conducted virtually. Both events will feature a fireside chat with management. Investors can access a live webcast and find a replay on the company's website, which will be available for 30 days post-event. 2seventy bio focuses on developing innovative immuno-oncology cell therapies to disrupt cancer treatment.

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- 2seventy bio, Inc. (Nasdaq: TSVT) announced today that members of the management team will participate in the following upcoming investor conferences:

• Guggenheim Oncology Conference 2023, fireside chat on February 9 at 9:00am ET, the St. Regis New York
• SVB Securities Global Biopharma Conference, fireside chat on February 15 at 10:00am ET, virtual

A live webcast will be available via the Investors and Media section of 2seventy bio’s website at https://ir.2seventybio.com/. A replay will be archived on 2seventy bio’s site for 30 days following the event.

About 2seventy bio
Our name, 2seventy bio, reflects why we do what we do - TIME. Cancer rips time away, and our goal is to work at the maximum speed of translating human thought into action – 270 miles per hour – to give the people we serve more time. We are building the leading immuno-oncology cell therapy company, focused on discovering and developing new therapies that truly disrupt the cancer treatment landscape. With a deep understanding of the human body’s immune response to tumor cells and how to translate cell therapies into practice, we’re applying this knowledge to deliver next generation cellular therapies that focus on a broad range of hematologic malignancies, including the first FDA-approved CAR T cell therapy for multiple myeloma, as well as solid tumors. Our research and development is focused on delivering therapies that are designed with the goal to “think” smarter and faster than the disease. Importantly, we remain focused on accomplishing these goals by staying genuine and authentic to our “why” and keeping our people and culture top of mind every day.

For more information, visit www.2seventybio.com.

Follow 2seventy bio on social media: Twitter and LinkedIn.

2seventy bio is a trademark of 2seventy bio, Inc.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230201005572/en/

Investors:

Elizabeth Pingpank, 860-463-0469

elizabeth.pingpank@2seventybio.com

Media:

Morgan Adams, 774-313-9852

morgan.adams@2seventybio.com

Source: 2seventy bio, Inc.

FAQ

What are the dates and times for the 2seventy bio investor conferences?

2seventy bio will participate in the Guggenheim Oncology Conference on February 9 at 9:00 am ET and the SVB Securities Global Biopharma Conference on February 15 at 10:00 am ET.

Where can I access the live webcast for the 2seventy bio conferences?

The live webcast for 2seventy bio's conferences can be accessed via the Investors and Media section of their website.

How long will the replay of the 2seventy bio conference be available?

The replay of the 2seventy bio conference will be archived on their website for 30 days following the event.

What is the primary focus of 2seventy bio's research and development?

2seventy bio focuses on developing breakthrough immuno-oncology cell therapies targeting hematologic malignancies and solid tumors.